| Medical and Health Sciences | Lifetime | 410 | US 221 | 99.98 |
| Medical and Health Sciences | 2021-2025 | 9 | US 7 | 100.00 |
| Biological Sciences | 2021-2025 | 457 | US 96 | 99.51 |
| Oncology | Lifetime | 24 | US 13 | 99.96 |
| Pulmonary and Respiratory Medicine | Lifetime | 42 | US 21 | 99.95 |
| Cancer Research | Lifetime | 109 | US 62 | 99.42 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 1 | US 1 | 100.00 |
| Oncology | 2021-2025 | 1 | US 1 | 99.99 |
| Cancer Research | 2021-2025 | 5 | US 2 | 99.86 |
| Radiology, Nuclear Medicine and Imaging | 2021-2025 | 245 | US 86 | 95.49 |
| Genetics | 2021-2025 | 545 | US 204 | 84.49 |
| Advanced Breast Cancer Therapies | Lifetime | 1 | US 1 | 99.95 |
| Cancer Treatment and Pharmacology | Lifetime | 5 | US 3 | 99.97 |
| HER2/EGFR in Cancer Research | Lifetime | 7 | US 4 | 99.94 |
| Breast Cancer Treatment Studies | Lifetime | 21 | US 11 | 99.90 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 74 | US 42 | 99.79 |
| Cancer-related Molecular Pathways | Lifetime | 78 | US 51 | 99.60 |
| PI3K/AKT/mTOR signaling in cancer | Lifetime | 51 | US 31 | 99.47 |
| PARP inhibition in cancer therapy | Lifetime | 39 | US 22 | 99.24 |
| Monoclonal and Polyclonal Antibodies Research | Lifetime | 328 | US 204 | 99.37 |
| Chronic Lymphocytic Leukemia Research | Lifetime | 187 | US 100 | 99.43 |
| Cancer Diagnosis and Treatment | Lifetime | 171 | US 93 | 98.85 |
| Cancer Genomics and Diagnostics | Lifetime | 410 | US 238 | 99.23 |
| Lung Cancer Research Studies | Lifetime | 363 | US 164 | 98.58 |
| Cancer Cells and Metastasis | Lifetime | 445 | US 205 | 98.06 |
| Peptidase Inhibition and Analysis | Lifetime | 573 | US 265 | 98.02 |
| Estrogen and related hormone effects | Lifetime | 473 | US 284 | 98.23 |
| Angiogenesis and VEGF in Cancer | Lifetime | 344 | US 160 | 97.82 |
| Brain Metastases and Treatment | Lifetime | 284 | US 168 | 97.93 |
| Chemotherapy-related skin toxicity | Lifetime | 76 | US 47 | 96.72 |
| Colorectal Cancer Treatments and Studies | Lifetime | 692 | US 288 | 97.99 |
| BRCA gene mutations in cancer | Lifetime | 411 | US 218 | 97.18 |
| Radiopharmaceutical Chemistry and Applications | Lifetime | 786 | US 313 | 96.55 |
| Economic and Financial Impacts of Cancer | Lifetime | 439 | US 282 | 95.50 |
| Cancer-related cognitive impairment studies | Lifetime | 207 | US 133 | 95.31 |
| Cancer survivorship and care | Lifetime | 839 | US 389 | 95.58 |
| Nausea and vomiting management | Lifetime | 431 | US 157 | 94.72 |
| Biosimilars and Bioanalytical Methods | Lifetime | 445 | US 169 | 93.52 |
| Pathogenesis and Treatment of Hiccups | Lifetime | 224 | US 87 | 80.26 |
| Breast Cancer Treatment Studies | 2021-2025 | 1 | US 1 | 99.99 |
| Cancer Treatment and Pharmacology | 2021-2025 | 1 | US 1 | 99.99 |
| Advanced Breast Cancer Therapies | 2021-2025 | 1 | US 1 | 100.00 |
| Cancer-related Molecular Pathways | 2021-2025 | 1 | US 1 | 99.95 |
| HER2/EGFR in Cancer Research | 2021-2025 | 2 | US 1 | 99.98 |
| Monoclonal and Polyclonal Antibodies Research | 2021-2025 | 10 | US 5 | 99.72 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 55 | US 18 | 99.77 |
| Chronic Lymphocytic Leukemia Research | 2021-2025 | 20 | US 11 | 99.64 |
| PI3K/AKT/mTOR signaling in cancer | 2021-2025 | 3 | US 3 | 98.93 |
| Cancer Genomics and Diagnostics | 2021-2025 | 59 | US 30 | 99.43 |
| PARP inhibition in cancer therapy | 2021-2025 | 44 | US 19 | 98.50 |
| Cancer Cells and Metastasis | 2021-2025 | 90 | US 23 | 96.05 |
| Lung Cancer Research Studies | 2021-2025 | 210 | US 77 | 97.35 |
| Lung Cancer Treatments and Mutations | 2021-2025 | 525 | US 181 | 96.68 |
| CAR-T cell therapy research | 2021-2025 | 855 | US 461 | 95.17 |
| Estrogen and related hormone effects | 2021-2025 | 121 | US 53 | 92.05 |
| Radiopharmaceutical Chemistry and Applications | 2021-2025 | 284 | US 83 | 93.81 |
| Economic and Financial Impacts of Cancer | 2021-2025 | 237 | US 152 | 93.16 |
| Colorectal Cancer Treatments and Studies | 2021-2025 | 469 | US 151 | 94.39 |
| Cancer Diagnosis and Treatment | 2021-2025 | 275 | US 66 | 86.86 |
| Peptidase Inhibition and Analysis | 2021-2025 | 645 | US 158 | 89.63 |
| Cancer-related cognitive impairment studies | 2021-2025 | 203 | US 92 | 87.04 |
| Cancer Risks and Factors | 2021-2025 | 505 | US 184 | 82.49 |
| Chemotherapy-related skin toxicity | 2021-2025 | 102 | US 43 | 79.60 |
| Neutropenia and Cancer Infections | 2021-2025 | 771 | US 263 | 70.88 |
| Pathogenesis and Treatment of Hiccups | 2021-2025 | 153 | US 39 | 37.05 |